Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
2023-10-13
临床3期上市批准临床结果
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced upcoming data presentations for tenapanor for hyperphosphatemia at the American Society of Nephrology (ASN) Kidney Week 2023 meeting to be held in Philadelphia, PA, November 1-5, 2023. XPHOZAH (tenapanor), discovered and developed by Ardelyx, is an investigational first-in-class phosphate absorption inhibitor.
Ardelyx will present four poster presentations highlighting data from two trials in patients with hyperphosphatemia on maintenance dialysis in the U.S. Additionally, the company’s collaboration partner for tenapanor in Japan, Kyowa Kirin Co, Ltd. (Kyowa Kirin), will present key results from two Phase 3 studies of tenapanor in a similar patient population in Japan.
Information regarding ASN's Kidney Week, including copies of presentation abstracts, can be found at https://www.asn-online.org/education/kidneyweek.
Ardelyx Poster Presentations:
Title: Optimal Initiation of Tenapanor Treatment Analyzed by Baseline Phosphate Binder Dose: A Sub-analysis of the OPTIMIZE StudyAuthors:Stuart Sprague, Jill Meyer, David Rosenbaum, Susan Edelstein, Yang Yang, Suling Zhao, David SpiegelPoster Number:TH-PO143Date/Time:November 2, 2023 from 10:00 AM to 12:00 PM ET
Title: Patient Education Improves Tenapanor Tolerability in OPTIMIZE StudyAuthors:Stephen Fadem, David Tietjen, David Spiegel, Susan Edelstein, Yang Yang, David RosenbaumPoster Number:TH-PO147Date/Time:November 2, 2023 from 10:00 AM to 12:00 PM ET
Title: Safety Analysis of Tenapanor Monotherapy vs Sevelamer Carbonate in Patients on Maintenance Dialysis with HyperphosphatemiaAuthors:Arnold Silva, German T. Hernandez, David Spiegel, David Rosenbaum, Susan Edelstein, Yang Yang, Suling Zhao, Laura WilliamsPoster Number:TH-PO146Date/Time:November 2, 2023 from 10:00 AM to 12:00 PM ET
Title: Tenapanor in Combination with Phosphate Binders Improves Short and Long- Term Control of Serum Phosphate (sP) in Patients on Dialysis with HyperphosphatemiaAuthors:Daniel Weiner, Robert Lynn, David Spiegel, Susan Edelstein, Yang Yang, David RosenbaumPoster Number:FR-PO318Date/Time:November 3, 2023 from 10:00 AM to 12:00 PM
Kyowa Kirin Poster Presentations:
Title: Tenapanor effect on decrease in phosphate binder pill burden for hyperphosphatemia in Japanese patients undergoing hemodialysis: A phase 3 long-term studyPoster Number:TH-PO144Date/Time:November 2, 2023 from 10:00 AM to 12:00 PM
Title: Efficacy and safety of tenapanor in Japanese peritoneal dialysis patients with hyperphosphatemia: Results of a phase 3 studyPoster Number:TH-PO145Date/Time:November 2, 2023 from 10:00 AM to 12:00 PM
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop, and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx’s first approved product, IBSRELA® (tenapanor) is available in the United States and Canada. Ardelyx is also developing XPHOZAH® (tenapanor). Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
Kimia Keshtbod
kkeshtbod@ardelyx.com
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。